Thus, our in vivo results clearly indicated that delivery of the CD73 inhibitor with the pH‐responsive nanocarrier was superior to the conventional delivery method, and F127ZIF‐8AB680 significantly enhanced the therapeutic efficacy of immune checkpoint blockade in treatment of EGFR mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.